• News

"Advaxis Announces Initiation of Phase 1-2 Trial of ADXS-HPV in Head and Neck Cancer Conducted by Icahn School of Medicine at Mount Sinai"

  • Reuters
  • New York, NY
  • (November 20, 2013)

Advaxis, Inc, a leader in developing the next generation of cancer immunotherapies, announced that the Icahn School of Medicine at Mount Sinai (ISMMS) will initiate a Phase 1/2 study of ADXS-HPV in 25 patients with Human Papilloma Virus (HPV)-positive head and neck cancer, a type of cancer which is increasing at an epidemic rate. "We are excited to be partnering with Mount Sinai in their search for improved treatment of head and neck cancers," commented Dr. Robert Petit, Chief Scientific Officer of Advaxis. "This will be the first study in which we can evaluate the effects of ADXS-HPV in patients when they are newly diagnosed with cancer and treat them with ADXS-HPV immunotherapy prior to any chemotherapy and/or radiation." Read more